Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NeuBase Therapeutics, Inc. NBSE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NeuBase Therapeutics, Inc. (NBSE) is a Biotechnology company in the Healthcare sector, currently trading at $0.38. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $34M (loss), growing at -15.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $6M against $23M equity (Debt-to-Equity (D/E) ratio 0.26, conservative). Current ratio is 5.92 (strong liquidity). Debt-to-assets is 18.3%. Total assets: $33M.

Analyst outlook: 3 / 6 analysts rate NBSE as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 40/100 (Partial), Income ?/100 (Fail).

NBSE SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NBSE

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
NBSE: +0%/yr revenue is, -15.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet NBSE: Debt-to-Equity (D/E) ratio 0.26 (conservative), Current ratio is 5.92 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NBSE: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 3 / 6 analysts rate NBSE as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.36-4.44
Volume89.7K
Avg Volume (30D)128.24K
Market Cap$1.42M
Beta (1Y)0.95
Share Statistics
EPS (TTM)-21.08
Shares Outstanding$1.62M
IPO Date2004-05-28
Employees37
CEOTodd P. Branning
Financial Highlights & Ratios
Gross Profit$-1.26M
EBITDA$-32.49M
Net Income$-34.23M
Operating Income$-33.32M
Total Cash$23.15M
Total Debt$6M
Net Debt$-17.16M
Total Assets$32.69M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering6
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS64132K2015

Price Chart

Track all markets on TradingView
NBSE
NeuBase Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.36 52WK RANGE 4.44

People Also View

NAMS
NAMS
NewAmsterdam Pharma Company N.V.
$34.44
-4.99%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 CMPX
CMPX
Compass Therapeutics, Inc.
$5.44
+4.62%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 IVA
IVA
Inventiva S.A.
$5.51
+9.98%
 YS
YS
YS Biopharma Co., Ltd.
$1.02
+9.68%
 LABP
LABP
Landos Biopharma, Inc.
$22.93
+0.57%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message